| Bioactivity | ODN 21158 is a potent G-modified TLR3 and TLR9 inhibitor. ODN 21158 shows no cytotoxic. ODN 21158 inhibits IFN-α secretion in a dose dependent manner[1]. |
| Invitro | ODN 21158 (0.01, 0.1, 1, 10 μM) shows no cytotoxic in human PBMCs[1].ODN 21158 (0.01, 0.1, 1, 10 μM; 24 h) inhibits IFN-α secretion in a dose dependent manner when stimulated with CpG-ODN 2216 (3 μM) in Human PBMCs[1].ODN 21158 (0.01, 0.1, 1, 10 μM; 48 h) stimulated with CpG-ODN 2006 (100 nM) failes to inhibit IL-6 release of PBMCs[1].ODN 21158 (0.01, 0.1, 1, 10 μM; 48 h) inhibits the release of IL-6 when stimulated with imiquimod (5 μg/ml) in human PBMCs[1].ODN 21158 (0.1, 1, 10 μM; 24 h) inhibits the release of IL-6 in B-cells when stimulated with imiquimod (5 μg/ml) and CpG-ODN 2006 (100 nM)[1]. Cell Cytotoxicity Assay[1] Cell Line: |
| Name | ODN 21158 |
| CAS | 1964506-31-7 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Römmler F, et al. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells. PLoS One. 2015 Feb 19;10(2):e0116703. |